Improved detection of recurrent bladder cancer using the bard BTA stat test

Michael F. Sarosdy, M'Liss A. Hudson, William J. Ellis, Mark S. Soloway, Ralph W deVere White, Joel Sheinfeld, Mark V. Jarowenko, Paul F. Schellhammer, Ed W. Schervish, Jay V. Patel, Gerald W. Chodak, Donald L. Lamm, Robert D. Johnson, Mary Henderson, George Adams, Brent A. Blumenstein, Kent R. Thoelke, Randy D. Pfalzgraf, Heather A. Murchison, Sharon L. Brunelle

Research output: Contribution to journalArticlepeer-review

165 Scopus citations


Objectives. To evaluate the BTA stat Test in the detection of recurrent bladder cancer. Methods. Sensitivity and specificity were determined using frozen voided urine samples from patients with recurrent bladder cancer, volunteers, patients with nonurologic conditions, and patients with a history of bladder cancer but free of disease. Results of cytology and the original BTA Test were compared with the sensitivity of the BTA stat Test in a large subgroup of the patients with cancer. Results. The BTA stat Test detected 147 (67%) of 220 recurrent cancers. For those urine samples with previous cytologic and BTA Test results available, cytology had a sensitivity of 23%, the BTA Test 44%, and the BTA star Test 58% for detection of recurrent cancer (P < 0.001, star versus cytology). The specificity of the BTA star Test was 72% for benign genitourinary disease and 95% in healthy volunteers. Conclusions. The BTA star Test has high sensitivity and is significantly superior to voided urine cytologic analysis in the detection of recurrent bladder cancer.

Original languageEnglish (US)
Pages (from-to)349-353
Number of pages5
Issue number3
StatePublished - Sep 1997
Externally publishedYes

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Improved detection of recurrent bladder cancer using the bard BTA stat test'. Together they form a unique fingerprint.

Cite this